VYNE Therapeutics Inc.VYNENASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +10.53% | +106.12% | -65.15% | +39.67% | +54.76% |
| Gross Profit Growth | +10.53% | +106.12% | -65.15% | +39.67% | +48.81% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +37.16% | +0.22% | +0.41% | +0.37% | +0.42% |
| Weighted Average Shares Diluted Growth | +37.16% | +0.22% | +0.41% | +0.37% | +0.42% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -31.51% | -38.45% | -48.39% | -52.58% | -54.92% |
| Book Value per Share Growth | -57.20% | -47.18% | -48.28% | -49.68% | -46.92% |
| Debt Growth | -53.74% | -65.00% | -82.76% | -100.00% | -100.00% |
| R&D Expense Growth | +220.34% | +65.16% | -33.19% | -48.71% | -69.27% |
| SG&A Expenses Growth | -18.40% | -13.13% | -16.97% | -8.74% | -25.17% |